The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

The identification of senescent cells is a long-standing unresolved challenge, owing to their intrinsic heterogeneity and the lack of universal markers. In this Comment, we discuss the recent ...

Recent studies presented at the ESMO meeting affirm the safety of breastfeeding for breast cancer survivors and highlight the ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Telehealth respiratory group Respiri says a sales deal with a US group will help the firm achieve cash-flow breakeven status ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...